Vpriv velaglucerase alfa regulatory update

Shire said EMA's CHMP issued a positive opinion recommending approval of its Lexington, Mass., manufacturing facility to produce Gaucher's disease therapy Vpriv velaglucerase alfa. Shire's Cambridge, ...